GBT Global Blood Therapeutics Inc.

73.13
-6.61  -8%
Previous Close 79.74
Open 79.64
Price To Book 6.69
Market Cap 4,404,725,280
Shares 60,231,441
Volume 1,551,954
Short Ratio
Av. Daily Volume 1,349,153
Stock charts supplied by TradingView

NewsSee all news

  1. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on January 1, 2020, the compensation committee of GBT's board of directors granted

  2. GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday,

  3. GBT Secures $150 Million Non-Dilutive Term Loan Financing

    Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT)

  4. GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

    Collaboration Combines GBT's Therapeutic Area Leadership with Power of Syros' Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin Syros to Receive $20 Million Upfront, Three Years of Preclinical

  5. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on December 1, 2019, the compensation committee of GBT's board of directors granted

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.
GBT440
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
FDA Approval announced November 25, 2019.
Voxelotor
Sickle cell disease
Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .
GBT440 HOPE-KIDS 1
Sickle cell disease - children age 6-17.

Latest News

  1. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on January 1, 2020, the compensation committee of GBT's board of directors granted

  2. GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday,

  3. GBT Secures $150 Million Non-Dilutive Term Loan Financing

    Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta™ (voxelotor) Commercialization SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT)

  4. GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

    Collaboration Combines GBT's Therapeutic Area Leadership with Power of Syros' Gene Control Platform to Find New Medicines to Induce Fetal Hemoglobin Syros to Receive $20 Million Upfront, Three Years of Preclinical

  5. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on December 1, 2019, the compensation committee of GBT's board of directors granted

  6. GBT Announces Participation at Upcoming Investor Conferences in December

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in December 2019: Evercore

  7. FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

    First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of age and older1

  8. GBT Reports Recent Business Progress and Third Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported recent business progress and financial results for the third quarter ended September 30,

  9. GBT Announces Upcoming Data Presentations at 61st American Society of Hematology Annual Meeting & Exposition

    Abstracts Include Three Post-hoc Analyses of Phase 3 HOPE Study Clinical Data Data Further Support the Safety and Efficacy of Voxelotor for Sickle Cell Disease (SCD) Examination of Real-world Evidence Further

  10. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ:GBT) today announced that on November 1, 2019, the compensation committee of GBT's board of directors

  11. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ:GBT) today announced that on October 1, 2019, the compensation committee of GBT's board of directors granted

  12. GBT Announces Upcoming Presentations at the 47th Annual National Sickle Cell Disease Association of America (SCDAA) Convention

    SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that four abstracts related to its sickle cell disease (SCD) research have been accepted

  13. GBT to Host Analyst & Investor Day on October 8 in New York

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ:GBT) today announced that it will host an Analyst & Investor Day to provide an update to the investment

  14. GBT Announces Participation at the 2019 Cantor Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City

  15. GBT Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease

    Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with

  16. GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 1, 2019, the compensation committee of GBT's board of directors

  17. GBT Announces Participation at the 2019 Morgan Stanley Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New

  18. GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

    Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream

  19. GBT and Sickle Cell Disease Association of America to Host 8th Annual Sickle Cell Disease (SCD) Therapeutics Conference

    Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream